Shares closed 8.6% higher at ₹1,119 after the company reported Q2 FY27 net profit of ₹52 crore, up 12.7% YoY, and revenue of ₹197 crore, a 20.9% jump from the ₹163 crore quarter a year earlier.
EBITDA rose 32% to ₹73.2 crore, pushing the margin to 37.2% from 34.1% last year, a 310‑basis‑point improvement that outpaces the 29% YoY growth seen in the broader pharma sector and aligns with the 38% margin reported by peers such as Glenmark.
The company, founded in 1989 and listed on the BSE under the ticker SUDPHARMA, specializes in pharmaceutical excipients and specialty nutrition ingredients. Its 52‑week high of ₹1,378 and low of ₹524.05 places the stock near a bullish trend, with analysts noting that the recent margin expansion could bolster investor sentiment.
Sudeep Pharma has not yet issued forward guidance, but management highlighted its focus on expanding the product portfolio and optimizing the supply chain. The company is slated to release its FY28 results in June, and analysts are watching for any walk‑away from the current positive trajectory amid global commodity price volatility.